

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE FAX RECEIVED

In re Application of: SUN et al.

APR 24 2003

Serial No.: 10/054,935

Examiner: Susan Ungar, Ph.D.

GROUP 1600

Filed: January 25, 2002

Group Art Unit: 1642

For: Breast Cancer Transcription Factor Gene and Uses


OFFICIAL**INFORMATION DISCLOSURE STATEMENT**

Consideration of the attached information is requested. In accordance with 37 CFR 1.97(b)(3), this information disclosure statement is being submitted before the mailing date of a first Office Action on the merits, and therefore no fee is required.

The Commissioner is hereby authorized to charge any additional fees to Deposit Account 501761.

Respectfully submitted,


By:



Richard M. Lebovitz (Reg. No. 37,067)
OriGene Technologies, Inc.
6 Taft Court, Suite 100
Rockville, MD 20850

Filed: April 23, 2003

Docket: 16U 107 R1

CERTIFICATE OF TRANSMISSION	
I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office (Fax No. (703) 308-4242)	
on	23 April 2003
(Date)	
	
(Signature)	
Richard Lebovitz	
(Name)	
TOTAL PAGES: 9	

Sheet 1 of 1 ()

Form PTO-1449	ATTY DOCKET NO. 16U 107 R1	APPLICATION NO. 10/054,935
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT SUN et al.	
(Use several sheets if necessary)	FILING DATE January 25, 2002	GROUP 1642

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

	XM_058887. NCBI SEQUENCE REVISION HISTORY and SEQUENCE RECORD DATED 10-DEC-2001.
	AK014463. NCBI SEQUENCE REVISION HISTORY and SEQUENCE RECORD DATED 19-JAN 2002.

EXAMINER _____ **DATE CONSIDERED** _____
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.